Abstract
dc:descriptionThe spondyloarthritides, particularly ankylosing spondylitis (AS) and psoriatic arthritis (PsA), have been related to an increased cardiovascular morbidity and mortality. The purpose of the study was to investigate whether spondyloarthritis patients have an increased prevalence of cardiovascular risk factors and the role of inflammation in disturbing them. In a cross-sectional study, non-diabetic patients with spondyloarthritis were compared to age- and sex-matched apparently healthy control subjects as regards classic cardiovascular risk factors. It was demonstrated that patients were significantly more often smokers, had lower high density lipoprotein (HDL) cholesterol levels and an elevated atherogenic index (total cholesterol/HDL). After adjustment for smoking, patients still had lower HDL values. Furthermore, PsA patients had a higher waist-to-hip ratio (WHR, an index of abdominal obesity) and serum urate levels than controls, while they more often fulfilled the criteria for the metabolic syndrome. In univariate analysis, laboratory markers of inflammation were significantly negatively correlated with HDL and apolipoprotein (Apo) AI levels, whereas, particularly in PsA, there was an additional positive correlation between inflammatory markers and obesity measures (body mass index, WHR), as well as the atherogenic index. Spondyloarthritis patients had a significantly increased carotid intima-media thickness compared to controls, although this ceased to be significant after adjustment for smoking. A group of patients with active spondyloarthritis who had not been on immunomodulatory treatment were followed for up to one year after treatment initiation. Although treatment with TNFα inhibitors and/or synthetic disease-modifying antirheumatic drugs (and low-dose glucocorticoids in 3 patients) produced a significant improvement in laboratory and clinical measures of disease activity both at 6 and 12 months, there was no significant change in either the obesity measures or serum lipid levels. It was only at 6 months that a significant decline in ApoB levels was noted coupled with a small borderline improvement in ApoAI levels and the ApoB/ApoAI ratio. However, these alterations were not sustained up to 12 months. In conclusion, spondyloarthritis patients have an increased prevalence of classic cardiovascular risk factors (smoking, low HDL and in PsA abdominal obesity and metabolic syndrome). Inflammation appears to adversely affect these factors. Immunomodulatory treatment does not seem to substantially modify obesity measures or the lipid profile, although its influence on actual cardiovascular event rates remains unknown.
Degree
thesis:*- Grantor dc:publisher
- University of Ioannina
- Year dc:date
- 2013
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Papagoras, Charalampos
- Παπαγοράς, Χαράλαμπος
Subjects
dc:subject × 20- Σπονδυλαρθρίτιδα
- Αγκυλοποιητική σπονδυλίτιδα
- Ψωριασική αρθρίτιδα
- Καρδιαγγειακός κίνδυνος
- Δυσλιπιδαιμία
- Μεταβολικό σύνδρομο
- Αθηροσκλήρυνση
- Φλεγμονή
- Spondyloarthritis
- Ankylosing spondylitis
- Psoriatic arthritis
- Cardiovascular risk
- Dyslipidemias
- Metabolic syndrome
- Atherosclerosis
- Inflammation
- Ιατρική και Επιστήμες Υγείας
- Κλινική Ιατρική
- Medical and Health Sciences
- Clinical Medicine
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/29383